Mumbai: Pharma major Lupin Limited (Lupin) won the coveted India Pharma Leader Award at the India Pharma 2020 and India Medical Device 2020 conference.
This was the 5th edition of the event organized by FICCI in collaboration with the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. Lupin was presented the award by Shri. Vijay Rupani, Chief Minister of Gujarat and Shri. D.V. Sadananda Gowda, Union Minister, Ministry of Chemicals and Fertilizers, Government of India.
Speaking on this win, Nilesh D. Gupta, Managing Director, Lupin said, “We are delighted to receive the India Pharma Leader Award from the Department of Pharmaceuticals, Government of India. It is indeed a moment of pride for us. This award acknowledges our contributions toward strengthening the Indian Pharmaceuticals Market and recognizes our all-round performance.”
This year, the event was held at Ahmedabad from March 5 – 7, 2020. The event theme focused on “Clarity on Changing Regulatory Scenarios,” and witnessed participation of more than 1,200 delegates from all over India.
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
Twitter: www.twitter.com/LupinGlobal
LinkedIn: www.linkedin.com/company/lupin
Facebook: www.facebook.com/LupinWorld
For further information or queries please contact –
Arvind Bothra Head – Investor Relations/Corporate M&A Email: arvindbothra@lupin.com | Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com |
